Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 5594
Gene Symbol: MAPK1
MAPK1
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.100 Biomarker BEFREE ERK2 but not ERK1 mediates HGF-induced motility in non-small cell lung carcinoma cell lines. 23549785

2013

Entrez Id: 5594
Gene Symbol: MAPK1
MAPK1
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.100 Biomarker BEFREE ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small-cell lung cancer cells to osimertinib. 31821539

2020

Entrez Id: 5594
Gene Symbol: MAPK1
MAPK1
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.100 Biomarker BEFREE Activation of the RAS/RAF/MEK/ERK pathway may confer resistance to chemotherapy in non-small cell lung cancer (NSCLC). 31200828

2019

Entrez Id: 5594
Gene Symbol: MAPK1
MAPK1
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.100 Biomarker BEFREE All these findings indicate that Ph is able to inhibit NSCLC A549 cell growth by inducing apoptosis through P38 MAPK and JNK1/2 pathways, and therefore may prove to be an adjuvant to the treatment of NSCLC. 26503828

2015

Entrez Id: 5594
Gene Symbol: MAPK1
MAPK1
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.100 Biomarker BEFREE Collectively, matrine activates p38 pathway leading to a caspase-dependent apoptosis by inducing generation of ROS in NSCLC cells and may be a potential chemical for NSCLC. 24026034

2013

Entrez Id: 5594
Gene Symbol: MAPK1
MAPK1
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.100 Biomarker BEFREE Combining IGF1R and MAP-ERK kinase blockade led to significant effects on viability in human non-small cell lung cancer (NSCLC) cell lines and in 2 mouse models of oncogenic KRAS-driven lung cancer. 23658296

2013

Entrez Id: 5594
Gene Symbol: MAPK1
MAPK1
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.100 Biomarker BEFREE CONCLUSIONS The results demonstrated that XJR can inhibit proliferation, invasion, and migration, and induce apoptosis of NSCLC by blocking the p38 MAPK pathway, which shows the potential of XJR as a new treatment of NSCLC. 31590176

2019

Entrez Id: 5594
Gene Symbol: MAPK1
MAPK1
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.100 Biomarker BEFREE CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC. 31273063

2019

Entrez Id: 5594
Gene Symbol: MAPK1
MAPK1
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.100 Biomarker BEFREE Differential expression and activation of epidermal growth factor receptor 1 (EGFR1), ERK, AKT, STAT3, and TWIST1 in nonsmall cell lung cancer (NSCLC). 24117170

2013

Entrez Id: 5594
Gene Symbol: MAPK1
MAPK1
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.100 Biomarker BEFREE EZH2 overexpression induces murine lung cancers that are similar to human NSCLC with high EZH2 expression and low levels of phosphorylated AKT and ERK, implicating biomarkers for EZH2 inhibitor sensitivity. 27312177

2016

Entrez Id: 5594
Gene Symbol: MAPK1
MAPK1
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.100 Biomarker BEFREE FOXM1 regulated by the ERK pathway can mediate TGF-β1-induced EMT in NSCLC and is a potential target for the treatment of NSCLC. 25700356

2014

Entrez Id: 5594
Gene Symbol: MAPK1
MAPK1
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.100 Biomarker BEFREE Here we demonstrate that EPO, at pharmacological concentrations, can activate three major signalling cascades, viz. the Jak2/STAT5, Ras/ERK and PI3K/Akt pathways in non-small cell lung carcinoma (NSCLC) cell lines. 16909043

2006

Entrez Id: 5594
Gene Symbol: MAPK1
MAPK1
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.100 Biomarker BEFREE Here, we examined the consequences and mechanisms of TRAIL-induced MAPKs p38 and JNK in non-small cell lung cancer (NSCLC) cells. 23456625

2013

Entrez Id: 5594
Gene Symbol: MAPK1
MAPK1
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.100 Biomarker BEFREE HYSA suppressed LPS-mediated proliferation, migration, invasion, and EMT in A549 and H1299 cells by inhibiting the PI3K/Akt/mTOR and ERK/MAPK signaling pathways, indicating that HYSA may be a potential candidate to treat inflammation-mediated NSCLC. 31055884

2019

Entrez Id: 5594
Gene Symbol: MAPK1
MAPK1
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.100 Biomarker BEFREE IL-22 Confers EGFR-TKI Resistance in NSCLC via the AKT and ERK Signaling Pathways. 31750252

2019

Entrez Id: 5594
Gene Symbol: MAPK1
MAPK1
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.100 GeneticVariation BEFREE In addition, mutant KRAS knockdown sensitized the NSCLCs to p38 and EGFR inhibitors. 21306997

2011

Entrez Id: 5594
Gene Symbol: MAPK1
MAPK1
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.100 Biomarker BEFREE In conclusion, EGCG overcomes Gef resistance by inhibiting autophagy and augmenting cell death through targeting ERK pathway in NSCLC. 31440060

2019

Entrez Id: 5594
Gene Symbol: MAPK1
MAPK1
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.100 GeneticVariation BEFREE In conclusion, LncRNA BC087858 could promote cells invasion and induce non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT via up- regulating ZEB1 and Snail in NSCLC. 27409677

2016

Entrez Id: 5594
Gene Symbol: MAPK1
MAPK1
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.100 AlteredExpression BEFREE In summary, our results support the role of ERK, AKT and TAK1 in mediating the expression of PD‑L1 during the EMT process, and indicate a promising strategy of PD‑L1‑targeted therapy for the clinical treatment of NSCLC. 29901173

2018

Entrez Id: 5594
Gene Symbol: MAPK1
MAPK1
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.100 Biomarker BEFREE In this study we explore the ability of Cd to activate JNK, p38 and ERK, including their effects on Cd-mediated growth inhibition and apoptosis in a human non-small cell lung carcinoma cell line, CL3. 10874022

2000

Entrez Id: 5594
Gene Symbol: MAPK1
MAPK1
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.100 Biomarker BEFREE In this study, the aim was to explore further the role of MAPK members, including JNK, p38 and extracellular signal-regulated kinase (ERK) in BPIQ-induced apoptosis and anti-migration of human non-small cell lung cancer (NSCLC) cells. 28286419

2017

Entrez Id: 5594
Gene Symbol: MAPK1
MAPK1
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.100 Biomarker BEFREE Knockdown of PAK1 Inhibits the Proliferation and Invasion of Non-Small Cell Lung Cancer Cells Through the ERK Pathway. 31394555

2019

Entrez Id: 5594
Gene Symbol: MAPK1
MAPK1
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.100 AlteredExpression BEFREE KRAS is frequently mutated in nonsmall cell lung cancer (NSCLC), resulting in the activation of the MAPK/ERK kinase (MEK)/ERK pathway. 20358631

2010

Entrez Id: 5594
Gene Symbol: MAPK1
MAPK1
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.100 GeneticVariation BEFREE LKB1 deficiency renders non-small-cell lung cancer cells sensitive to ERK inhibitors.: ERK inhibitors in LKB1 mutated NSCLC. 31634668

2020

Entrez Id: 5594
Gene Symbol: MAPK1
MAPK1
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.100 Biomarker BEFREE Low expression of Mig-6 is associated with poor survival outcome in NSCLC and inhibits cell apoptosis via ERK-mediated upregulation of Bcl-2. 24573418

2014